# INTERVIEW: Deltex Medical Group Positioned Well and Increased Interest

- Link: https://www.directorstalkinterviews.com/interview-deltex-medical-group-positioned-well-increased-interest/412750849
- Published: 2018-05-10T08:53:52+01:00
- Author: Giles Arbor

**Deltex Medical Group** (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about
its 2017 year end results. Ewan talks us through the highlights, explains whats 
been happening operationally this year, the strategy for the next 12 months and 
what investors can look forward to in the near future.

Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies.
Deltex Medical’s proprietary ODM is the only technology to measure blood flow in
the central circulation in real time. Minimally invasive, easy to set up and quick
to focus, the technology generates a low-frequency ultrasound signal, which is highly
sensitive to changes in flow and measures them immediately. Deltex has been the 
only company in the enhancedhaemodynamic space to build a robust and credible evidence
base proving the clinical and economic benefits of its core technology, ODM which
is proven to reduce complications suffered by patients after surgery and save hospitals
the costs of treating those complications.

Deltex Medical’s CardioQ-ODM+ platform also now provides clinicians with two further
advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography
is an entirely non-invasive monitoring technology which creates an electrical field
across the chest and measures the disruption to this field when the heart pumps 
blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis
to give doctors information on changes in the circulation and is particularly suited
to monitoring lower risk or haemodynamicallystable patients.

 

Company goal

Haemodynamic management is now becoming widely accepted as an important major new
medical modality. Consequently, the Company’s focus is on maximising value from 
the opportunities presented as enhanced haemodynamic management is adopted into 
routine clinical practice around the world. The Company aims to provide clinicians
with a single platform, a ‘haemodynamicworkstation’, which offers them a range of
technologies from simple to sophisticated to be deployed according to the patient’s
condition and skill and expertise of the user. Doing this will enable the Company
to partner healthcare providers to support modern haemodynamic management across
the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a
number of territories worldwide, operating directly in the UK, USA, Spain and Canada
and through distribution arrangements in a further 30 countries.

Share on: